open access

Vol 27, No 6 (2022)
Research paper
Published online: 2022-11-02
Get Citation

Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study

Soniya Mohammed1, Dinesan M1, Ajayakumar T1
DOI: 10.5603/RPOR.a2022.0113
·
Rep Pract Oncol Radiother 2022;27(6):1026-1036.
Affiliations
  1. Department of Radiation Oncology, Government Medical College Kozhikode Kerala, India

open access

Vol 27, No 6 (2022)
Original research articles
Published online: 2022-11-02

Abstract

Background: Glioblastoma multiforme (GBM) is the most common and aggressive primary intracranial tumor. Despite modern therapies, it is still fatal with tremendously poor prognosis with a median survival of 14 months. Even though mean survival and progression-free survival (PFS) are considered as primary response measure, it is important to assess the effects of therapies on disease burden and health-related quality of life (HRQoL). Changes in quality of life (QoL) indicates the impact of cytotoxic therapy and may aid in defining response in the absence of quantifiable endpoints like tumor regression.

The objective was to assess 2-year survival and quality of life in GBM patients who underwent primary surgery followed by chemo-radiotherapy and 6-month adjuvant chemotherapy with temozolomide. 

Materials and methods: Single-institution retrospective study of 60 patients of GBM from 2015 to 2017. Data regarding patient factors, disease factors, and treatment factors were collected and survival was calculated.

Results: 60 patients with GBM were analyzed, male to female ratio was 1.6:1. Patients most commonly presented with headache. Most common tumour site is the frontal lobe. The median overall survival (OS) was 10 months. The 1-year and 2-year survival rates were 30% and 6.7%, respectively. Compared to before surgery patients have showed improved emotional, social and role functioning in Post radiotherapy period. There was a decrease in symptoms like pain, headache and seizures.

Conclusions: OS and QoL in GBM patients remains poor despite constant research and studies. Maximum safe resection followed by adjuvant temozolomide has shown improvement in OS. Post-surgery and adjuvant radiotherapy patients have shown a decrease in symptoms and better QoL.

Abstract

Background: Glioblastoma multiforme (GBM) is the most common and aggressive primary intracranial tumor. Despite modern therapies, it is still fatal with tremendously poor prognosis with a median survival of 14 months. Even though mean survival and progression-free survival (PFS) are considered as primary response measure, it is important to assess the effects of therapies on disease burden and health-related quality of life (HRQoL). Changes in quality of life (QoL) indicates the impact of cytotoxic therapy and may aid in defining response in the absence of quantifiable endpoints like tumor regression.

The objective was to assess 2-year survival and quality of life in GBM patients who underwent primary surgery followed by chemo-radiotherapy and 6-month adjuvant chemotherapy with temozolomide. 

Materials and methods: Single-institution retrospective study of 60 patients of GBM from 2015 to 2017. Data regarding patient factors, disease factors, and treatment factors were collected and survival was calculated.

Results: 60 patients with GBM were analyzed, male to female ratio was 1.6:1. Patients most commonly presented with headache. Most common tumour site is the frontal lobe. The median overall survival (OS) was 10 months. The 1-year and 2-year survival rates were 30% and 6.7%, respectively. Compared to before surgery patients have showed improved emotional, social and role functioning in Post radiotherapy period. There was a decrease in symptoms like pain, headache and seizures.

Conclusions: OS and QoL in GBM patients remains poor despite constant research and studies. Maximum safe resection followed by adjuvant temozolomide has shown improvement in OS. Post-surgery and adjuvant radiotherapy patients have shown a decrease in symptoms and better QoL.

Get Citation

Keywords

overall survival; quality of life; glioblastoma multiforme; temozolomide

About this article
Title

Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 27, No 6 (2022)

Article type

Research paper

Pages

1026-1036

Published online

2022-11-02

Page views

449

Article views/downloads

78

DOI

10.5603/RPOR.a2022.0113

Bibliographic record

Rep Pract Oncol Radiother 2022;27(6):1026-1036.

Keywords

overall survival
quality of life
glioblastoma multiforme
temozolomide

Authors

Soniya Mohammed
Dinesan M
Ajayakumar T

References (17)
  1. Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014; 16(7): 896–913.
  2. Zhang YH, Li Z, Zeng T, et al. Distinguishing Glioblastoma Subtypes by Methylation Signatures. Front Genet. 2020; 11: 604336.
  3. Dubrow R, Darefsky AS. Demographic variation in incidence of adult glioma by subtype, United States, 1992-2007. BMC Cancer. 2011; 11: 325.
  4. Krex D, Klink B, Hartmann C, et al. German Glioma Network. Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10): 2596–2606.
  5. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987–996.
  6. Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011; 104(3): 639–646.
  7. Kalkanis SN, Quiñones-Hinojosa A, Buzney E, et al. Quality of life following surgery for intracranial meningiomas at Brigham and Women's Hospital: a study of 164 patients using a modification of the functional assessment of cancer therapy-brain questionnaire. J Neurooncol. 2000; 48(3): 233–241.
  8. Cella D, Chang CH, Lai JS, et al. Advances in quality of life measurements in oncology patients. Semin Oncol. 2002; 29(3 Suppl 8): 60–68.
  9. Mahalakshmi P, Vanisree AJ. Quality of life measures in glioma patients with different grades: A preliminary study. Indian J Cancer. 2015; 52(4): 580–585.
  10. Neuwelt AJ, Nguyen TM, Fu R, et al. Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis. CNS Oncol. 2014; 3(4): 267–273.
  11. Green H, Paul M, Vidal L, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82(9): 1052–1059.
  12. Bello-Alvarez C, Camacho-Arroyo I. Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones. Biol Sex Differ. 2021; 12(1): 28.
  13. Munshi A, Jalali R. Therapy for glioma: Indian perspective. Indian J Cancer. 2009; 46(2): 127–131.
  14. Brown TJ, Brennan MC, Li M, et al. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2016; 2(11): 1460–1469.
  15. SongTao Qi, Lei Yu, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci. 2012; 103(2): 269–273.
  16. Taphoorn M, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005; 6(12): 937–944.
  17. Taphoorn MJB, van den Bent MJ, Mauer MEL, et al. European Organisation for Research and Treatment of Cancer. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007; 25(36): 5723–5730.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl